biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Why do we still get buying of shares from tine ti time?

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Feb 28, 2024 9:49pm

116 Views

Post# 35905446

RE:RE:RE:Why do we still get buying of shares from tine ti time?

@adamfeuerstein

Feb 27

$DNLI - Baker Brothers is the lead investor in today's PIPE. They'll get a board seat as part of the deal, per the SEC filings.

prophetoffactz wrote:

narmac wrote: My understanding is at least one entity is interested in BTI,,,,the question is,,,Does the science actually work??,,,,,I am of the opinion it must have issues, and thats assuming a middleof the road scenario!!,,,,I thinks we were fed bovine excrement the past 10 years on this puppy!!!,,,

One entity could be big if J&J has still been researching the technology.

The S&P Biotech ETF is also up 60% in the last four months and is at multi-year highs. That could provide an opportunity to relaunch. In June BTI said: "The current economic environment and market conditions for small-cap development stage biopharmaceutical companies continue to be very challenging."